Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00229710
Status:
TERMINATED
Last Update Posted:
2010-11-19
First Post:
2005-09-28
Brief Title:
GALLEX 9 Safety and Tolerability of Oral Tesaglitazar When Added to Insulin Therapy in Patients With Type 2 Diabetes
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
An Open-Label Multi-Center Long-Term Extension Study to Evaluate the Safety and Tolerability of Oral Tesaglitazar 05mg When Added to Insulin Therapy in Patients With Type 2 Diabetes Mellitus GALLEX 9
Status:
TERMINATED
Status Verified Date:
2010-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The development program has been terminated
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a 140-week open-label multi-center long-term extension study from GALLANT 9 to monitor the safety and tolerability of oral tesaglitazar 05 mg and insulin in patients with type 2 diabetes during up to 140 weeks of treatment The total duration including treatment and follow-up is 143 weeks
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None